Fosun Pharma obtained China rights to tenapanor, an Ardelyx treatment for irritable bowel syndrome with constipation (IBS-C), in a $125 million agreement. Tenapanor is also expected to treat hyperphosphatemia related to chronic kidney disease. Ardelyx, a San Francisco area company, has completed US Phase III trials in which tenapanor met efficacy endpoints in both indications. The company describes the candidate as an oral, minimally systemic NHE3 inhibitor, and it expects to file for US approval next year.
Source: China Biotoday